EP2736546A1 - Medical device comprising a wetted hydrophilic coating - Google Patents
Medical device comprising a wetted hydrophilic coatingInfo
- Publication number
- EP2736546A1 EP2736546A1 EP12740180.0A EP12740180A EP2736546A1 EP 2736546 A1 EP2736546 A1 EP 2736546A1 EP 12740180 A EP12740180 A EP 12740180A EP 2736546 A1 EP2736546 A1 EP 2736546A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- wetting agent
- medical device
- coating
- hydrophilic polymer
- hydrophilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 82
- 239000011248 coating agent Substances 0.000 title claims abstract description 78
- 239000000080 wetting agent Substances 0.000 claims abstract description 69
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000009835 boiling Methods 0.000 claims abstract description 11
- 238000005461 lubrication Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- -1 glycerol ethers Chemical class 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 150000002314 glycerols Chemical class 0.000 claims description 3
- 150000002334 glycols Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000009736 wetting Methods 0.000 description 8
- 239000008199 coating composition Substances 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 230000003019 stabilising effect Effects 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GJKGAPPUXSSCFI-UHFFFAOYSA-N 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone Chemical compound CC(C)(O)C(=O)C1=CC=C(OCCO)C=C1 GJKGAPPUXSSCFI-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 239000004348 Glyceryl diacetate Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 150000007824 aliphatic compounds Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical class NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019443 glyceryl diacetate Nutrition 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920001289 polyvinyl ether Polymers 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229940044613 1-propanol Drugs 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000004608 Heat Stabiliser Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000001334 alicyclic compounds Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000007798 antifreeze agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960005335 propanol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B5/00—Packaging individual articles in containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, jars
- B65B5/04—Packaging single articles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/10—Materials for lubricating medical devices
Definitions
- the invention is directed to the use of a wetting agent having a boiling point higher than 100 °C and a viscosity lower than 500 mPa.s, wherein the wetting agent can comprise water in an amount between 0 and 4.9 wt% based on the total weight of the wetting agent for the lubrication of a hydrophilic polymer coating.
- the invention further relates to a medical device comprising a hydrophilic polymer coating that is wetted by a wetting agent having boiling point higher than 100 °C and a viscosity lower than 500 mPa.s, wherein the wetting agent can comprise water in an amount between 0 and 4.9 wt% based on the total weight of the wetting agent, a method for the preparation of a medical device and a package comprising a medical device.
- cardiovascular catheters, syringes, and membranes need to have a lubricant applied to the outer and/or inner surface to facilitate insertion into and removal from the body and/or to facilitate drainage of fluids from the body.
- Lubricious properties are also required so as to minimize soft tissue damage upon insertion or removal.
- such medical devices may have a hydrophilic surface coating or layer which becomes lubricious and attains low-friction properties upon wetting, i.e. applying a wetting fluid for a certain time period prior to insertion of the device into the body of a patient.
- a coating or layer which becomes lubricious after wetting is hereinafter referred to as a hydrophilic coating.
- a coating obtained after wetting is hereinafter referred to as a lubricious coating.
- lubricious is defined as having a smooth or slippery surface.
- wetting fluids water, water- containing mixtures further comprising one or more organic solvents and/or one or more dissolved components, such as salts.
- a wetting fluid can also be a body fluid or a saline solution having (approximately) physiological osmolarity.
- the medical devices can be wetted (and thereby become lubricious) immediately prior to use.
- medical devices with a hydrophilic coating have been introduced that are sterile-packaged in a package that contains enough wetting fluid to keep the coating wetted (and thus lubricious).
- WO-0405909A1 discloses the use of plasticizers in a cross-linked hydrophilic coating of a hydrophilic polymer on a substrate. The plasticizers form part of the polymer solution that is applied to the substrate. After application the polymer solution is dried and cured.
- the substrate can be a medical device, such as a catheter, guide wire or endoscope.
- the medical devices that are coated with the hydrophilic coating are wetted with water before use on a patient.
- the plasticizers have the effect that a hydrophilic coating is provided showing high abrasion resistance and low friction coefficient when wet.
- EP-1809345A1 discloses a medical device having a wetted hydrophilic coating comprising a coating composition containing a hydrophilic polymer and a wetting agent comprising water and one or more lubricant(s).
- the wetting agent comprises one or more lubricants in a total amount between 0.1 and 95 % by weight.
- the medical devices have a low friction surface, have an extended dry-out period and do not drip or have a reduced tendency to drip.
- hydrophilic coatings have the disadvantage that water is used for the lubrication of the hydrophilic coatings.
- water By using water as the main component in a wetting agent the hydrophilic coating will dry out and will thus not be lubricous for a long time.
- the hydrophilic coating will usually not be lubricous anymore within a time period of 15 minutes after wetting or after removal of a medical device from the package.
- a wetting agent having a boiling point higher than 100 °C and a viscosity lower than 500 mPa.s wherein the wetting agent can comprise water in an amount between 0 and 4.9 wt% based on the total weight of the wetting agent can be used for the lubrication of a hydrophilic polymer coating on a substrate, where after the lubricious hydrophilic coating will stay lubricous for a time period that is much longer than 15 minutes.
- a further advantage is that the lubricious hydrophilic coatings do not drip.
- the wetting agent has a boiling point higher than 100 °C, preferably higher than 200 °C.
- the boiling point is determined at ambient pressure.
- a high boiling point of the wetting agent corresponds to a low amount of evaporation of the wetting agent from the lubricous hydrophilic coating. This means that the hydrophilic coating will remain lubricous for a longer time.
- the wetting agent can be one liquid or a mixture of liquids.
- the wetting agent can comprise water, but only in a minor amount.
- the amount of water in the wetting agent is at most 4.9 weight% based on the total weight of wetting agent.
- the amount of water preferably is lower than 4 weight%, more preferably lower than 1 weight%.
- the wetting agent has a viscosity lower than 500 mPa.s. This is determined by at a temperature of 25 °C on a viscometer according to ASTM D445.
- the viscosity of water is 1 mPa.s.
- the viscosity of the wetting agent is preferably below 100 mPa.s.
- the viscosity of the wetting agent is preferably higher than 1 mPa.s; more preferably higher than 5 mPa.s.
- a low viscosity of the wetting agent corresponds to a low amount of friction between the lubricious hydrophilic coating and another surface.
- the wetting agent preferably comprises at least one hydroxyl group. More preferably, the wetting agent can be chosen from the group consisting of glycerol esters, glycerol ethers, glycols, glycolesters and glycolethers. Examples of wetting agents are glycerol, monoacetin, diacetin and diacetone alcohol.
- the wetting agents are used for the lubrication of a hydrophilic polymer coating.
- the hydrophilic coating may be any coating which comprises a hydrophilic medium that absorbs and/or adsorbs the wetting agent. This can be any coating comprising hydrophilic polymers, an antimicrobial coating, a non-fouling coating or a drug eluting coating.
- a hydrophilic polymer coating comprises a hydrophilic polymer capable of providing hydrophilicity to the coating, which polymer may be synthetic or bio-derived and can be blends or copolymers of both.
- Suitable hydrophilic polymers include but are not limited to poly(lactams), for example polyvinylpyrollidone (PVP), polyurethanes, homo- and copolymers of acrylic and methacrylic acid, polyvinyl alcohol, polyvinylethers, maleic anhydride based copolymers, polyesters, vinylamines, polyethyleneimines, polyethyleneoxides, poly(carboxylic acids), polyamides, polyanhydrides, polyphosphazenes, cellulosics, for example methyl cellulose, carboxymethyl cellulose, hydroxymethyl cellulose, and hydroxypropylcellulose, heparin, dextran, polysacharrides, for example chitosan, hyaluronic acid, alginates, gelatin, and chitin, polyester
- polypeptides polypeptides, short chain peptides, proteins, and oligonucleotides.
- the hydrophilic polymer coating comprises poly(lactams), for example polyvinylpyrollidone (PVP), polyurethanes, homo- and copolymers of acrylic and methacrylic acid, polyvinyl alcohol, polyvinylethers, maleic anhydride based copolymers, polyesters, vinylamines, polyethyleneimines or polyethyleneoxides. More preferably the hydrophilic polymer coating comprises polyvinylpyrrolidone (PVP).
- PVP polyvinylpyrollidone
- the hydrophilic polymer has a molecular weight in the range of about 8,000 to about 5,000,000 g/mol, preferably in the range of about 20,000 to about 3,000,000 g/mol and more preferably in the range of about 200,000 to about 2,000,000 g/mol.
- the hydrophilic polymer may be used in the coating in more than 1 wt%, for example more than 5 wt%, or more than 50 wt%, based on the total weight of the dry coating.
- the hydrophilic polymer can be present up to 99 wt%, or up to 95 %, based on the total weight of the dry coating.
- the hydrophilic polymer may for instance be a prepolymer, i.e. a polymer comprising one or more polymerisable groups, in particular one or more radically polymerisable groups such as one or more vinyl groups.
- a prepolymer having an average number of polymerisable groups per molecule of more than 1 is in particular suitable.
- the average number of reactive groups is at least 1 .2, more preferably at least 1 .5, in particular at least 2.0.
- the average number of groups is up to 64, more preferably in the range of up to 15, in particular in the range of up to 8, more in particular up to 7.
- polymerisable groups may be cured in the presence of a photo-initiator, in particular by the formation of grafts when the formulation is exposed to light.
- the hydrophilic coating composition may be in the form of a solution or a dispersion comprising a liquid medium.
- a liquid medium that allows application of the hydrophilic coating formulation on a surface would suffice.
- liquid media are alcohols, like methanol, ethanol, propanol, butanol or respective isomers and aqueous mixtures thereof or acetone, methylethyl ketone, tetrahydrofuran, dichloromethane, toluene, and aqueous mixtures or emulsions thereof.
- the hydrophilic coating composition according to the invention may additionally include various additives includes conventional ingredients like pigments, dyes, dispersing and stabilising agents (usually surfactants or emulsifiers), rheology control agents, flow-promoting agents, extenders, defoaming agents, plasticisers, thickeners, heat stabilisers, levelling agents, anti-cratering agents, fillers, sedimentation inhibitors, UV absorbers, antioxidants, organic co-solvents, wetting agents, fungicides, bacteriocides, anti-freeze agents, coalescents, waxes and the like introduced at any stage of the production process or subsequently.
- the hydrophilic coating can be coated on a substrate which may be selected from a range of geometries and materials.
- the substrate may have a texture, such as porous, non-porous, smooth, rough, even or uneven.
- the substrate supports the hydrophilic coating on its surface.
- the hydrophilic coating can be on all areas of the substrate or on selected areas.
- the hydrophilic coating can be applied to a variety of physical forms, including films, sheets, rods, tubes, molded parts (regular or irregular shape), fibers, fabrics, and particulates.
- Suitable surfaces are surfaces that provide the desired properties such as porosity, hydrophobicity, hydrophilicity, colorisability, strength, flexibility, permeability, elongation, abrasion resistance and tear resistance. Examples of suitable surfaces are for instance surfaces that consist of or comprise metals, plastics, ceramics, glass and/or composites.
- the hydrophilic coating may be applied directly to the said surfaces or may be applied to a pretreated or coated surface. The pretreatment or coating can be designed to aid adhesion of the
- hydrophilic coating to the substrate.
- the hydrophilic polymer coating is coated on a medical device.
- the medical device can be an implantable device or an extracorporeal device.
- the devices can be of short-term temporary use or of long-term permanent
- suitable devices are those that are typically used to provide for medical therapy and/or diagnostics in heart rhythm disorders, heart failure, valve disease, vascular disease, diabetes, neurological diseases and disorders, orthopedics, neurosurgery, oncology, ophthalmology, and ENT surgery.
- Suitable examples of medical devices include, but are not limited to, a stent, stent graft, anastomotic connector, synthetic patch, lead, electrode, needle, guide wire, catheter, sensor, surgical instrument, angioplasty balloon, wound drain, shunt, tubing, infusion sleeve, urethral insert, pellet, implant, blood oxygenator, pump, vascular graft, vascular access port, heart valve, annuloplasty ring, suture, surgical clip, surgical staple, pacemaker, implantable defibrillator, neurostimulator, orthopedic device, cerebrospinal fluid shunt, implantable drug pump, spinal cage, artificial disc, replacement device for nucleus pulposus, ear tube, intraocular lens and any tubing used in minimally invasive surgery.
- Devices that are particularly suited to be used in the present invention include medical devices or components such as catheters, for example intermittent catheters, guidewires, stents, syringes, metal and plastic implants, contact lenses and medical tubing.
- the hydrophilic polymer coating can be applied to the substrate by for example dip-coating. Other methods of application include spray, wash, vapor deposition, brush, roller and other methods known in the art.
- the hydrophilic polymer coating may have one or more layers.
- One layer may be a primer layer useful for attaching the coating layer to the medical device.
- the invention is further related to a method for the preparation of a medical device comprising the steps of:
- wetting agent with a boiling point higher than 100 °C and a viscosity lower than 500 mPa.s, wherein the wetting agent can comprise water in an amount between 0 and 4.9 wt% based on the total weight of the wetting agent,
- the hydrophilic polymer coating on the medical device must be wetted by the wetting agent.
- the term "wetted” is generally known in the art and - in a broad sense - means "containing a wetting agent”. In particular the term is used herein to describe a coating that contains sufficient wetting agent to be lubricious.
- a lubricious coating has a Coefficient of Friction (COF), as defined below, lower than 0.15.
- COF Coefficient of Friction
- concentration of the wetting agent usually a wetted coating contains at least 10 wt. % of wetting agent, based on the dry weight of the coating, preferably at least 50 wt. %, based on the dry weight of the coating, more preferably at least 100 wt. % based on the dry weight of the coating.
- an uptake of wetting agent of about 300-500 wt. % is feasible.
- a lubricious coating is obtained with a dry-out time longer than 15 minutes as determined on the Harland Friction tester.
- the dry-out time is the duration of the coating remaining lubricious after the device has been taken out of the wetting agent wherein it has been stored and wetted or after the device has been taken out of the package wherein it has been stored in a wetted condition. Dry-out time can be determined by measuring the coefficient of friction as a function of time the catheter had been exposed to air on the Harland Friction tester. The dry-out time is the point in time wherein the coefficient of friction reaches a value of 0.2 or higher, or in a stricter test 0.15 or higher. The protocol is as indicated in the Examples.
- a lubricious hydrophilic coating is obtained with a coefficient of friction lower than 0.20 as determined on the Harland Friction tester.
- a coating is considered lubricious if it has a friction as measured on a Harland FTS Friction Tester of 0.20 or less at a clamp-force of 100 g and a pull speed of 1 cm/s, preferably of 0.15 or less.
- the protocol is as indicated in the Examples.
- the medical device is sterilized. Sterilization can be achieved by applying the proper combinations of heat, chemicals and/or irradiation.
- Heat sterilization can be performed in an autoclave, wherein steam is heated to 120-135 °C.
- the medical device is for instance contacted with ethylene oxide (EtO), ozone or hydrogen peroxide.
- Sterilization by irradiation can, for instance, be performed by electron beam, x-ray or gamma ray irradiation.
- the hydrophilic coating and or the wetting agent may comprise additives that protect the coating against a detrimental effect of radicals formed during sterilization.
- additives are for example aliphatic compounds, alicyclic compounds and/or antioxidants.
- any aliphatic stabilising compound and/or alicyclic stabilising compound may be used, in particular any such compound that is physiologically allowable and preferably non-toxic in the used concentration.
- a stabilising compound with a relatively low molecular weight is particularly suitable, such as a compound with a molecular weight of less than
- a low molecular weight compound may have one or more of the following advantages, compared to a compound having a higher molecular weight:
- Particularly preferred aliphatic and/or alicyclic stabilising compounds include alcohols, ethers, aldehydes, ketones, amides, esters, thiols, thioesters, organic acids and combinations thereof.
- Highly preferred are (saturated) aliphatic compounds selected from the group consisting of (saturated) aliphatic alcohols, ethers, aldehydes, ketones amides, esters, thiols, thioesters, organic acids and combinations thereof.
- Preferred alcohols include alkylene glycols, such as diethyleneglycol, triethyleneglycol, tetraethyleneglycol, propyleneglycol, dipropyleneglycol,
- triprolyeneglycol (low molecular) ethoxylated or propoxylated alcohols and/or amines like ethanolamine, diethanolamine, triethanolamine, polyethylene glycol (PEG), in particular polyalkylene glycols having a Mw up to about 600 g/mol lower aliphatic alcohols - in particular C1 -C8 alcohols, more in particular C2-C4 alcohol, such as isopropanol, ethanol, 1 -propanol and 1 -butanol - and combinations thereof. Good results have further been achieved with a carbohydrate, in particular a
- monosaccharide more in particular glucose.
- Preferred ethers include polyalkylene glycols, such as PEG.
- Suitable aldehydes include C1 -C8 aldehydes.
- Preferred aldehydes include formaldehyde, acetaldehyde and butanal.
- Suitable ketones include C3-C8 ketones.
- Preferred ketones include acetone and methylethylketone.
- Suitable organic acids include C1 -C8 organic acids.
- Preferred organic acids include formic acid.
- the invention is further directed to a package containing a medical device or a part of a medical device comprising a lubricated hydrophilic coating, which package is impermeable to vapor.
- the package can, for instance, be made of plastic or aluminum foil.
- the package can contain additional wetting agent.
- the package comprises a medical device that is sterilized.
- the primer formulation was prepared by dissolving the components below in ethanol.
- Irgacure 2959 (supplied by Sigma Aldrich) 0.20 % (w/w)
- the hydrophilic coating formulation was prepared by dissolving the components below in a water/ethanol mixture 1 :1 based on weight. Weight%
- PVC tubes with a diameter of 14 Fr and a length of 30 cm were coated on a Harland PCX coater 175/24.
- the PVC tubes were first dip- coated with the primer coating formulation and cured according the dip protocol for the primer in table 1 . Subsequently the hydrophilic coating formulation was applied and cured according the dip protocol for the hydrophilic coating. Temperature and humidity during application were respectively 21 °C +1-2 °C and 40% +/- 15%.
- the Harland PCX coater/175/24 was equipped with a Harland Medical systems UVM 400 lamp. Intensity of the lamps of the Harland PCX
- coater/175/24 was on average 60 mW/cm 2 and was measured using a Solatell Sola Sensor 1 equipped with an International Light detector SED005#989, Input Optic:
- the tubes were dipped in the wetting agent, immersed for 2 minutes and thereafter extracted from the wetting agent with a speed of 1 cm/s.
- the wetted coatings were evaluated directly after removal from the wetting agent.
- the viscosity of a wetting agent was determined on a viscometer according to ASTM D445 at a temperature of 25 °C. Lubricity test
- HFT Harland FTS5000 Friction Tester
- test description was inserted when "run test” was activated.
- a sample was fastened in the sample holder..
- the transport of the tester was moved to the desired position and the protocol was activated by pushing "start”.
- the data were saved after finishing.
- the sample holder was removed from the tester and subsequently the catheter was removed from the holder.
- the measured coefficient of friction (COF) is used to rate the performance of the coating.
- the COF is defined as the measured friction ⁇ clamp force.
- the COF was determined on a sample after 10, 15 and 30 minutes of drying. The drying time started directly after removal of the sample from the wetting agent.
- a C0FO.15 is judged as good.
- a COF between 0.15 and 0.20 is judged as too high; a COF>0.20 is judged as bad.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Food Science & Technology (AREA)
- Materials For Medical Uses (AREA)
- Paints Or Removers (AREA)
Abstract
The invention is directed to the use of a wetting agent having a boiling point higher than 100 °C and a viscosity lower than 500 mPa.s, wherein the wetting agent comprises water in an amount between 0 and 4.9 wt% based on the total weight of the wetting agent, for the lubrication of a hydrophilic polymer coating. The invention further relates to a medical device comprising a hydrophilic polymer coating that is wetted by a wetting agent, a method for the preparation of a medical device and a package comprising a medical device.
Description
MEDICAL DEVICE COMPRISING A WETTED HYDROPHILIC COATING
The invention is directed to the use of a wetting agent having a boiling point higher than 100 °C and a viscosity lower than 500 mPa.s, wherein the wetting agent can comprise water in an amount between 0 and 4.9 wt% based on the total weight of the wetting agent for the lubrication of a hydrophilic polymer coating. The invention further relates to a medical device comprising a hydrophilic polymer coating that is wetted by a wetting agent having boiling point higher than 100 °C and a viscosity lower than 500 mPa.s, wherein the wetting agent can comprise water in an amount between 0 and 4.9 wt% based on the total weight of the wetting agent, a method for the preparation of a medical device and a package comprising a medical device.
Many medical devices, such as guide wires, urinary and
cardiovascular catheters, syringes, and membranes need to have a lubricant applied to the outer and/or inner surface to facilitate insertion into and removal from the body and/or to facilitate drainage of fluids from the body. Lubricious properties are also required so as to minimize soft tissue damage upon insertion or removal. Especially, for lubrication purposes, such medical devices may have a hydrophilic surface coating or layer which becomes lubricious and attains low-friction properties upon wetting, i.e. applying a wetting fluid for a certain time period prior to insertion of the device into the body of a patient. A coating or layer which becomes lubricious after wetting is hereinafter referred to as a hydrophilic coating. A coating obtained after wetting is hereinafter referred to as a lubricious coating. Herein lubricious is defined as having a smooth or slippery surface.
In the prior art the following wetting fluids are described; water, water- containing mixtures further comprising one or more organic solvents and/or one or more dissolved components, such as salts. According to the prior art a wetting fluid can also be a body fluid or a saline solution having (approximately) physiological osmolarity.
In principle, the medical devices can be wetted (and thereby become lubricious) immediately prior to use. However, from a user's point of view it is desirable to be able to use the device directly after opening of the packaging wherein it is stored. In view of this, medical devices with a hydrophilic coating have been introduced that are sterile-packaged in a package that contains enough wetting fluid to keep the coating wetted (and thus lubricious).
WO-0405909A1 discloses the use of plasticizers in a cross-linked hydrophilic coating of a hydrophilic polymer on a substrate. The plasticizers form part of the polymer solution that is applied to the substrate. After application the polymer solution is dried and cured. The substrate can be a medical device, such as a catheter, guide wire or endoscope. The medical devices that are coated with the hydrophilic coating are wetted with water before use on a patient. The plasticizers have the effect that a hydrophilic coating is provided showing high abrasion resistance and low friction coefficient when wet.
EP-1809345A1 discloses a medical device having a wetted hydrophilic coating comprising a coating composition containing a hydrophilic polymer and a wetting agent comprising water and one or more lubricant(s). The wetting agent comprises one or more lubricants in a total amount between 0.1 and 95 % by weight. The medical devices have a low friction surface, have an extended dry-out period and do not drip or have a reduced tendency to drip.
The above described hydrophilic coatings have the disadvantage that water is used for the lubrication of the hydrophilic coatings. By using water as the main component in a wetting agent the hydrophilic coating will dry out and will thus not be lubricous for a long time. The hydrophilic coating will usually not be lubricous anymore within a time period of 15 minutes after wetting or after removal of a medical device from the package.
It has now surprisingly been discovered that a wetting agent having a boiling point higher than 100 °C and a viscosity lower than 500 mPa.s, wherein the wetting agent can comprise water in an amount between 0 and 4.9 wt% based on the total weight of the wetting agent can be used for the lubrication of a hydrophilic polymer coating on a substrate, where after the lubricious hydrophilic coating will stay lubricous for a time period that is much longer than 15 minutes.
A further advantage is that the lubricious hydrophilic coatings do not drip.
The wetting agent has a boiling point higher than 100 °C, preferably higher than 200 °C. The boiling point is determined at ambient pressure.
A high boiling point of the wetting agent corresponds to a low amount of evaporation of the wetting agent from the lubricous hydrophilic coating. This means that the hydrophilic coating will remain lubricous for a longer time.
The wetting agent can be one liquid or a mixture of liquids. The wetting agent can comprise water, but only in a minor amount. The amount of water in
the wetting agent is at most 4.9 weight% based on the total weight of wetting agent. The amount of water preferably is lower than 4 weight%, more preferably lower than 1 weight%.
The wetting agent has a viscosity lower than 500 mPa.s. This is determined by at a temperature of 25 °C on a viscometer according to ASTM D445. The viscosity of water is 1 mPa.s. The viscosity of the wetting agent is preferably below 100 mPa.s. The viscosity of the wetting agent is preferably higher than 1 mPa.s; more preferably higher than 5 mPa.s. A low viscosity of the wetting agent corresponds to a low amount of friction between the lubricious hydrophilic coating and another surface.
The wetting agent preferably comprises at least one hydroxyl group. More preferably, the wetting agent can be chosen from the group consisting of glycerol esters, glycerol ethers, glycols, glycolesters and glycolethers. Examples of wetting agents are glycerol, monoacetin, diacetin and diacetone alcohol.
The wetting agents are used for the lubrication of a hydrophilic polymer coating. The hydrophilic coating may be any coating which comprises a hydrophilic medium that absorbs and/or adsorbs the wetting agent. This can be any coating comprising hydrophilic polymers, an antimicrobial coating, a non-fouling coating or a drug eluting coating.
A hydrophilic polymer coating comprises a hydrophilic polymer capable of providing hydrophilicity to the coating, which polymer may be synthetic or bio-derived and can be blends or copolymers of both. Suitable hydrophilic polymers include but are not limited to poly(lactams), for example polyvinylpyrollidone (PVP), polyurethanes, homo- and copolymers of acrylic and methacrylic acid, polyvinyl alcohol, polyvinylethers, maleic anhydride based copolymers, polyesters, vinylamines, polyethyleneimines, polyethyleneoxides, poly(carboxylic acids), polyamides, polyanhydrides, polyphosphazenes, cellulosics, for example methyl cellulose, carboxymethyl cellulose, hydroxymethyl cellulose, and hydroxypropylcellulose, heparin, dextran, polysacharrides, for example chitosan, hyaluronic acid, alginates, gelatin, and chitin, polyesters, for example polylactides, polyglycolides, and polycaprolactones, polypeptides, for example collagen, fibrins, elastin, albumin, oligo peptides,
polypeptides, short chain peptides, proteins, and oligonucleotides.
Preferably the hydrophilic polymer coating comprises poly(lactams), for example polyvinylpyrollidone (PVP), polyurethanes, homo- and copolymers of acrylic and methacrylic acid, polyvinyl alcohol, polyvinylethers, maleic anhydride based copolymers, polyesters, vinylamines, polyethyleneimines or polyethyleneoxides.
More preferably the hydrophilic polymer coating comprises polyvinylpyrrolidone (PVP).
Generally the hydrophilic polymer has a molecular weight in the range of about 8,000 to about 5,000,000 g/mol, preferably in the range of about 20,000 to about 3,000,000 g/mol and more preferably in the range of about 200,000 to about 2,000,000 g/mol. The hydrophilic polymer may be used in the coating in more than 1 wt%, for example more than 5 wt%, or more than 50 wt%, based on the total weight of the dry coating. The hydrophilic polymer can be present up to 99 wt%, or up to 95 %, based on the total weight of the dry coating.
The hydrophilic polymer may for instance be a prepolymer, i.e. a polymer comprising one or more polymerisable groups, in particular one or more radically polymerisable groups such as one or more vinyl groups.
For providing a cross-linked network, a prepolymer having an average number of polymerisable groups per molecule of more than 1 is in particular suitable. Preferably, the average number of reactive groups is at least 1 .2, more preferably at least 1 .5, in particular at least 2.0. Preferably the average number of groups is up to 64, more preferably in the range of up to 15, in particular in the range of up to 8, more in particular up to 7.
However, also a hydrophilic polymer which is free of such
polymerisable groups may be cured in the presence of a photo-initiator, in particular by the formation of grafts when the formulation is exposed to light.
The hydrophilic coating composition may be in the form of a solution or a dispersion comprising a liquid medium. Herein any liquid medium that allows application of the hydrophilic coating formulation on a surface would suffice. Examples of liquid media are alcohols, like methanol, ethanol, propanol, butanol or respective isomers and aqueous mixtures thereof or acetone, methylethyl ketone, tetrahydrofuran, dichloromethane, toluene, and aqueous mixtures or emulsions thereof.
The hydrophilic coating composition according to the invention may additionally include various additives includes conventional ingredients like pigments, dyes, dispersing and stabilising agents (usually surfactants or emulsifiers), rheology control agents, flow-promoting agents, extenders, defoaming agents, plasticisers, thickeners, heat stabilisers, levelling agents, anti-cratering agents, fillers, sedimentation inhibitors, UV absorbers, antioxidants, organic co-solvents, wetting agents, fungicides, bacteriocides, anti-freeze agents, coalescents, waxes and the like introduced at any stage of the production process or subsequently.
The hydrophilic coating can be coated on a substrate which may be selected from a range of geometries and materials. The substrate may have a texture, such as porous, non-porous, smooth, rough, even or uneven. The substrate supports the hydrophilic coating on its surface. The hydrophilic coating can be on all areas of the substrate or on selected areas. The hydrophilic coating can be applied to a variety of physical forms, including films, sheets, rods, tubes, molded parts (regular or irregular shape), fibers, fabrics, and particulates. Suitable surfaces are surfaces that provide the desired properties such as porosity, hydrophobicity, hydrophilicity, colorisability, strength, flexibility, permeability, elongation, abrasion resistance and tear resistance. Examples of suitable surfaces are for instance surfaces that consist of or comprise metals, plastics, ceramics, glass and/or composites. The hydrophilic coating may be applied directly to the said surfaces or may be applied to a pretreated or coated surface. The pretreatment or coating can be designed to aid adhesion of the
hydrophilic coating to the substrate.
Preferably, the hydrophilic polymer coating is coated on a medical device. The medical device can be an implantable device or an extracorporeal device. The devices can be of short-term temporary use or of long-term permanent
implantation. In certain embodiments, suitable devices are those that are typically used to provide for medical therapy and/or diagnostics in heart rhythm disorders, heart failure, valve disease, vascular disease, diabetes, neurological diseases and disorders, orthopedics, neurosurgery, oncology, ophthalmology, and ENT surgery.
Suitable examples of medical devices include, but are not limited to, a stent, stent graft, anastomotic connector, synthetic patch, lead, electrode, needle, guide wire, catheter, sensor, surgical instrument, angioplasty balloon, wound drain, shunt, tubing, infusion sleeve, urethral insert, pellet, implant, blood oxygenator, pump, vascular graft, vascular access port, heart valve, annuloplasty ring, suture, surgical clip, surgical staple, pacemaker, implantable defibrillator, neurostimulator, orthopedic device, cerebrospinal fluid shunt, implantable drug pump, spinal cage, artificial disc, replacement device for nucleus pulposus, ear tube, intraocular lens and any tubing used in minimally invasive surgery.
Devices that are particularly suited to be used in the present invention include medical devices or components such as catheters, for example intermittent catheters, guidewires, stents, syringes, metal and plastic implants, contact lenses and medical tubing.
The hydrophilic polymer coating can be applied to the substrate by for example dip-coating. Other methods of application include spray, wash, vapor deposition, brush, roller and other methods known in the art.
The hydrophilic polymer coating may have one or more layers. One layer may be a primer layer useful for attaching the coating layer to the medical device.
The invention is further related to a method for the preparation of a medical device comprising the steps of:
- providing a medical device that is at least partially coated with a hydrophilic
polymer coating,
- providing a wetting agent with a boiling point higher than 100 °C and a viscosity lower than 500 mPa.s, wherein the wetting agent can comprise water in an amount between 0 and 4.9 wt% based on the total weight of the wetting agent,
- contacting the part of the medical device that is coated with the hydrophilic
polymer coating with the wetting agent in such a way that the hydrophilic coating is lubricated by the wetting agent,
- optionally, sterilizing the medical device.
The hydrophilic polymer coating on the medical device must be wetted by the wetting agent. The term "wetted" is generally known in the art and - in a broad sense - means "containing a wetting agent". In particular the term is used herein to describe a coating that contains sufficient wetting agent to be lubricious. A lubricious coating has a Coefficient of Friction (COF), as defined below, lower than 0.15. In terms of the concentration of the wetting agent, usually a wetted coating contains at least 10 wt. % of wetting agent, based on the dry weight of the coating, preferably at least 50 wt. %, based on the dry weight of the coating, more preferably at least 100 wt. % based on the dry weight of the coating. For instance, in a particular embodiment of the invention an uptake of wetting agent of about 300-500 wt. % is feasible.
Preferably, a lubricious coating is obtained with a dry-out time longer than 15 minutes as determined on the Harland Friction tester. Within the context of the invention, the dry-out time is the duration of the coating remaining lubricious after the device has been taken out of the wetting agent wherein it has been stored and wetted or after the device has been taken out of the package wherein it has been stored in a wetted condition. Dry-out time can be determined by measuring the coefficient of friction as a function of time the catheter had been exposed to air on the Harland Friction tester. The dry-out time is the point in time wherein the coefficient of friction
reaches a value of 0.2 or higher, or in a stricter test 0.15 or higher. The protocol is as indicated in the Examples.
Preferably, a lubricious hydrophilic coating is obtained with a coefficient of friction lower than 0.20 as determined on the Harland Friction tester. A coating is considered lubricious if it has a friction as measured on a Harland FTS Friction Tester of 0.20 or less at a clamp-force of 100 g and a pull speed of 1 cm/s, preferably of 0.15 or less. The protocol is as indicated in the Examples.
Optionally, the medical device is sterilized. Sterilization can be achieved by applying the proper combinations of heat, chemicals and/or irradiation.
Heat sterilization can be performed in an autoclave, wherein steam is heated to 120-135 °C. During chemical sterilization the medical device is for instance contacted with ethylene oxide (EtO), ozone or hydrogen peroxide. Sterilization by irradiation can, for instance, be performed by electron beam, x-ray or gamma ray irradiation.
The hydrophilic coating and or the wetting agent may comprise additives that protect the coating against a detrimental effect of radicals formed during sterilization. These additives are for example aliphatic compounds, alicyclic compounds and/or antioxidants.
In principle any aliphatic stabilising compound and/or alicyclic stabilising compound may be used, in particular any such compound that is physiologically allowable and preferably non-toxic in the used concentration.
A stabilising compound with a relatively low molecular weight is particularly suitable, such as a compound with a molecular weight of less than
1000 g/mol, more in particular of 800 g/mol or less, preferably of 600 gram/mol or less. The use of a low molecular weight compound may have one or more of the following advantages, compared to a compound having a higher molecular weight:
Particularly preferred aliphatic and/or alicyclic stabilising compounds include alcohols, ethers, aldehydes, ketones, amides, esters, thiols, thioesters, organic acids and combinations thereof. Highly preferred are (saturated) aliphatic compounds selected from the group consisting of (saturated) aliphatic alcohols, ethers, aldehydes, ketones amides, esters, thiols, thioesters, organic acids and combinations thereof.
Preferred alcohols include alkylene glycols, such as diethyleneglycol, triethyleneglycol, tetraethyleneglycol, propyleneglycol, dipropyleneglycol,
triprolyeneglycol, (low molecular) ethoxylated or propoxylated alcohols and/or amines like ethanolamine, diethanolamine, triethanolamine, polyethylene glycol (PEG), in
particular polyalkylene glycols having a Mw up to about 600 g/mol lower aliphatic alcohols - in particular C1 -C8 alcohols, more in particular C2-C4 alcohol, such as isopropanol, ethanol, 1 -propanol and 1 -butanol - and combinations thereof. Good results have further been achieved with a carbohydrate, in particular a
monosaccharide, more in particular glucose.
Preferred ethers include polyalkylene glycols, such as PEG.
Suitable aldehydes include C1 -C8 aldehydes. Preferred aldehydes include formaldehyde, acetaldehyde and butanal.
Suitable ketones include C3-C8 ketones. Preferred ketones include acetone and methylethylketone.
Suitable organic acids include C1 -C8 organic acids. Preferred organic acids include formic acid.
The invention is further directed to a package containing a medical device or a part of a medical device comprising a lubricated hydrophilic coating, which package is impermeable to vapor. The package can, for instance, be made of plastic or aluminum foil. The package can contain additional wetting agent.
Preferably, the package comprises a medical device that is sterilized.
The invention will now be illustrated by the following, non-limiting examples.
Examples 1 -5 and Comparative Experiment A-H
Primer coating formulation
The primer formulation was prepared by dissolving the components below in ethanol.
PTGL1000(T-H)2 oligomer 4.25 % (w/w)
PVP K85 (supplied by BASF) 0.75 % (w/w)
Irgacure 2959 (supplied by Sigma Aldrich) 0.20 % (w/w)
Ethanol 96% (supplied by Merck) : 94.8 % (w/w)
The synthesis of PTGL1000(T-H)2 oligomer is described in
WO2007/065722.
Hydrophilic coating formulation
The hydrophilic coating formulation was prepared by dissolving the components below in a water/ethanol mixture 1 :1 based on weight. Weight%
PVP K85 5.20
Polyacrylamide-co-acrylic acid sodium salt (PAcA) 0.35
(supplied by Sigma Aldrich)
Irgacure 2959 (supplied by Sigma Aldrich) 1
Benzophenone 1
Ethanol (96%) 47.45
Water 45
Coating application
PVC tubes with a diameter of 14 Fr and a length of 30 cm were coated on a Harland PCX coater 175/24.
The PVC tubes were first dip- coated with the primer coating formulation and cured according the dip protocol for the primer in table 1 . Subsequently the hydrophilic coating formulation was applied and cured according the dip protocol for the hydrophilic coating. Temperature and humidity during application were respectively 21 °C +1-2 °C and 40% +/- 15%.
The Harland PCX coater/175/24 was equipped with a Harland Medical systems UVM 400 lamp. Intensity of the lamps of the Harland PCX
coater/175/24 was on average 60 mW/cm2 and was measured using a Solatell Sola Sensor 1 equipped with an International Light detector SED005#989, Input Optic:
W#1 1521 , filter: wbs320#27794. The IL1400A instruction manual of International Light was applied, which is available on the internet: www.intl-liqht.com. For the applied parameters in the PCX coater see Table 1 .
The tubes were dipped in the wetting agent, immersed for 2 minutes and thereafter extracted from the wetting agent with a speed of 1 cm/s. The wetted coatings were evaluated directly after removal from the wetting agent.
All measurements were performed at a relative humidity of 40-50%.
Table 1. Applied parameters in the PCX Coater
Test methods
Viscosity test
The viscosity of a wetting agent was determined on a viscometer according to ASTM D445 at a temperature of 25 °C.
Lubricity test
Lubricity tests were performed on a Harland FTS5000 Friction Tester (HFT). The protocol was selected: see Table 2 for HFT settings. Friction tester pads were used from Harland Medical Systems, P/N 102692, FTS5000 Friction Tester Pads, 0,125*0,5**0,125, 60 durometer.
Subsequently the desired test description was inserted when "run test" was activated. A sample was fastened in the sample holder.. The transport of the tester was moved to the desired position and the protocol was activated by pushing "start". The data were saved after finishing. The sample holder was removed from the tester and subsequently the catheter was removed from the holder.
Table 2. HFT settings
The measured coefficient of friction (COF) is used to rate the performance of the coating. The COF is defined as the measured friction\clamp force. The COF was determined on a sample after 10, 15 and 30 minutes of drying. The drying time started directly after removal of the sample from the wetting agent.
A C0FO.15 is judged as good. A COF between 0.15 and 0.20 is judged as too high; a COF>0.20 is judged as bad.
Table 3, Results of the lubricity test
The results obtained with triacetin show a high COF. It was observed that this compound was absorbed insufficiently by the coating.
The results obtained with mono- and diacetin show a low friction value that remained unchanged over the whole test period of 30 minutes. Even after remeasuring the samples after 16 hours in air almost no change in friction was observed (COF was 0.12).
Comparative experiments C-F show that the addition of water to the wetting agent shortens the time that a coating remains lubricious after the removal of the wetted coating from the wetting agent.
Claims
CLAIMS:
Use of a wetting agent having a boiling point higher than 100 °C and a viscosity lower than 500 mPa.s for the lubrication of a hydrophilic polymer coating on a substrate, wherein the wetting agent can comprise water in an amount between 0 and 4.9 wt% based on the total weight of the wetting agent. Use according to claim 1 , wherein the wetting agent comprises at least one hydroxyl group.
Use according to claim 1 or 2, wherein the wetting agent is chosen from the group comprising glycerol esters, glycerol ethers, glycols, glycolesters and glycolethers.
Medical device comprising a hydrophilic polymer coating that is wetted by a wetting agent having a boiling point higher than 100 °C and a viscosity lower than 500 mPa.s, wherein the wetting agent comprises water in an amount between 0 and 4.9 wt% based on the total weight of the wetting agent.
Medical device according to claim 4, wherein the wetting agent comprises at least one hydroxyl group.
Medical device according to claim 4 or 5, wherein the wetting agent is chosen from the group consisting of glycerol esters, glycerol ethers, glycols, glycolesters and glycolethers.
Medical device according to anyone of claims 4-6, wherein the hydrophilic polymer coating is crosslinked.
Medical device according to anyone of claims 4-7, wherein the hydrophilic polymer coating comprises polyvinylpyrrollidone (PVP).
Medical device according to anyone of claims 4-8, with a dry-out time longer than 15 minutes as determined on a Harland Friction tester.
Medical device according to anyone of claims 4-9, with a coefficient of friction lower than 0.2 as determined on a Harland Friction tester.
Method for the preparation of a medical device according to anyone of claims
4-10 comprising the steps of:
a. providing a medical device that is at least partially coated with a
hydrophilic polymer coating,
b. providing a wetting agent with a boiling point higher than 100 °C and a viscosity lower than 500 mPa.s, wherein the wetting agent comprises
water in an amount between 0 and 4.9 wt% based on the total weight of the wetting agent,
c. contacting the part of the medical device that is coated with the
hydrophilic polymer coating with the wetting agent in such a way that the hydrophilic coating is lubricated by the wetting agent,
d. optionally, sterilizing the medical device.
Package comprising a medical device according to anyone of claims 4-10, wherein the package is impermeable to vapor.
Package according to claim 12, wherein the medical device is sterilized.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12740180.0A EP2736546A1 (en) | 2011-07-29 | 2012-07-27 | Medical device comprising a wetted hydrophilic coating |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161513021P | 2011-07-29 | 2011-07-29 | |
| EP11175951 | 2011-07-29 | ||
| EP12740180.0A EP2736546A1 (en) | 2011-07-29 | 2012-07-27 | Medical device comprising a wetted hydrophilic coating |
| PCT/EP2012/064820 WO2013017547A1 (en) | 2011-07-29 | 2012-07-27 | Medical device comprising a wetted hydrophilic coating |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2736546A1 true EP2736546A1 (en) | 2014-06-04 |
Family
ID=47628651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP12740180.0A Withdrawn EP2736546A1 (en) | 2011-07-29 | 2012-07-27 | Medical device comprising a wetted hydrophilic coating |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20140190846A1 (en) |
| EP (1) | EP2736546A1 (en) |
| CN (1) | CN103561789A (en) |
| WO (1) | WO2013017547A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11951219B2 (en) | 2017-01-20 | 2024-04-09 | Hollister Incorporated | Method for sterilizing a substrate having a hydrophilic coating and sterilized substrates |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350703B (en) | 2009-05-13 | 2017-09-14 | Sio2 Medical Products Inc | Outgassing method for inspecting a coated surface. |
| WO2013170052A1 (en) | 2012-05-09 | 2013-11-14 | Sio2 Medical Products, Inc. | Saccharide protective coating for pharmaceutical package |
| US9458536B2 (en) | 2009-07-02 | 2016-10-04 | Sio2 Medical Products, Inc. | PECVD coating methods for capped syringes, cartridges and other articles |
| US11624115B2 (en) | 2010-05-12 | 2023-04-11 | Sio2 Medical Products, Inc. | Syringe with PECVD lubrication |
| US9878101B2 (en) | 2010-11-12 | 2018-01-30 | Sio2 Medical Products, Inc. | Cyclic olefin polymer vessels and vessel coating methods |
| US9272095B2 (en) | 2011-04-01 | 2016-03-01 | Sio2 Medical Products, Inc. | Vessels, contact surfaces, and coating and inspection apparatus and methods |
| US11116695B2 (en) | 2011-11-11 | 2021-09-14 | Sio2 Medical Products, Inc. | Blood sample collection tube |
| EP2776603B1 (en) | 2011-11-11 | 2019-03-06 | SiO2 Medical Products, Inc. | PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS |
| US20150297800A1 (en) | 2012-07-03 | 2015-10-22 | Sio2 Medical Products, Inc. | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS |
| CA2890066C (en) | 2012-11-01 | 2021-11-09 | Sio2 Medical Products, Inc. | Coating inspection method |
| US9903782B2 (en) | 2012-11-16 | 2018-02-27 | Sio2 Medical Products, Inc. | Method and apparatus for detecting rapid barrier coating integrity characteristics |
| JP6382830B2 (en) | 2012-11-30 | 2018-08-29 | エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド | Uniformity control of PECVD deposition on medical syringes, cartridges, etc. |
| US9764093B2 (en) | 2012-11-30 | 2017-09-19 | Sio2 Medical Products, Inc. | Controlling the uniformity of PECVD deposition |
| US9662450B2 (en) | 2013-03-01 | 2017-05-30 | Sio2 Medical Products, Inc. | Plasma or CVD pre-treatment for lubricated pharmaceutical package, coating process and apparatus |
| US9937099B2 (en) | 2013-03-11 | 2018-04-10 | Sio2 Medical Products, Inc. | Trilayer coated pharmaceutical packaging with low oxygen transmission rate |
| EP2971228B1 (en) | 2013-03-11 | 2023-06-21 | Si02 Medical Products, Inc. | Coated packaging |
| US20160017490A1 (en) | 2013-03-15 | 2016-01-21 | Sio2 Medical Products, Inc. | Coating method |
| WO2015148471A1 (en) | 2014-03-28 | 2015-10-01 | Sio2 Medical Products, Inc. | Antistatic coatings for plastic vessels |
| DK3283136T4 (en) | 2015-04-16 | 2025-01-02 | Hollister Inc | HYDROPHILIC COATINGS AND METHODS FOR FORMING THE SAME |
| EP3337915B1 (en) | 2015-08-18 | 2021-11-03 | SiO2 Medical Products, Inc. | Pharmaceutical and other packaging with low oxygen transmission rate |
| EP3281649A1 (en) | 2016-08-09 | 2018-02-14 | Teleflex Lifesciences | Wetting agent formulation |
| DK3570899T3 (en) * | 2017-01-20 | 2021-04-12 | Hollister Inc | PROCEDURES FOR STERILIZING A HYDROFILT COATED MEDICAL DEVICE |
| EP3721910B1 (en) | 2017-02-21 | 2023-11-01 | Hollister Incorporated | Radiation activated gels that release fluids and assemblies containing the same |
| DK3793627T3 (en) | 2018-05-17 | 2025-01-02 | Hollister Inc | HYDROPHILIC, MEDICAL PRODUCTS AND HYDRATION MEDIA FOR HYDRATION THEREOF |
| AU2020280047B2 (en) * | 2019-05-22 | 2022-05-26 | Hollister Incorporated | Packaged hydrophilic medical devices |
| JP7541522B2 (en) | 2019-08-21 | 2024-08-28 | テルモ株式会社 | Medical device and its manufacturing method |
| WO2021092388A1 (en) | 2019-11-08 | 2021-05-14 | Hollister Incorporated | Methods of making sleeved and packaged hydrophilic catheter assemblies |
| DK4054662T3 (en) | 2019-11-08 | 2024-07-22 | Hollister Inc | HYDROPHILIC MEDICINAL PRODUCTS AND HYDRATION MEDIA FOR HYDRATION THEREOF |
| WO2022103619A1 (en) | 2020-11-13 | 2022-05-19 | Hollister Incorporated | Catheter assemblies with interfacial ph controller |
| EP4062952B1 (en) * | 2021-03-23 | 2024-01-31 | Wellspect AB | Reusable hydrophilic urinary catheter assembly |
| AU2022286252A1 (en) | 2021-06-04 | 2023-12-21 | Hollister Incorporated | Methods of making sleeved hydrophilic catheter products |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2190289T5 (en) * | 1998-11-20 | 2007-08-01 | Coloplast A/S | A PROCEDURE TO STERILIZE A SANITARY DEVICE THAT HAS A HYDROPHYL COATING. |
| AU2003256448A1 (en) | 2002-07-03 | 2004-01-23 | Broadley Technologies Corporation | Reference electrode having a microfluidic flowing liquid junction and filter members |
| FR2870148B1 (en) * | 2004-05-12 | 2006-07-07 | Snecma Moteurs Sa | LOST WAX FOUNDRY PROCESS WITH CONTACT LAYER |
| PL2156852T3 (en) * | 2004-07-07 | 2011-11-30 | Coloplast As | Catheter comprising ESTANE 58212. |
| DK1809345T3 (en) | 2004-10-07 | 2009-07-13 | Coloplast As | Medical device with a wetted hydrophilic coating |
| DK1888127T3 (en) * | 2005-05-02 | 2010-05-31 | Coloplast As | Method of sterilizing a drug device with a hydrophilic coating |
| EP1957130B1 (en) | 2005-12-09 | 2010-09-15 | DSM IP Assets B.V. | Hydrophilic coating comprising a polyelectrolyte |
| WO2009139304A1 (en) * | 2008-05-16 | 2009-11-19 | テルモ株式会社 | Method of radiation sterilization of medical device having hydrophilic polymer coating |
| WO2010003419A2 (en) * | 2008-06-16 | 2010-01-14 | Coloplast A/S | Buffered swelling media for radiation sterilized hydrophilic coatings |
-
2012
- 2012-07-27 WO PCT/EP2012/064820 patent/WO2013017547A1/en not_active Ceased
- 2012-07-27 CN CN201280025917.6A patent/CN103561789A/en active Pending
- 2012-07-27 EP EP12740180.0A patent/EP2736546A1/en not_active Withdrawn
- 2012-07-27 US US14/115,920 patent/US20140190846A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2013017547A1 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11951219B2 (en) | 2017-01-20 | 2024-04-09 | Hollister Incorporated | Method for sterilizing a substrate having a hydrophilic coating and sterilized substrates |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140190846A1 (en) | 2014-07-10 |
| WO2013017547A1 (en) | 2013-02-07 |
| CN103561789A (en) | 2014-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2736546A1 (en) | Medical device comprising a wetted hydrophilic coating | |
| US8957125B2 (en) | Coating formulation for preparing a hydrophilic coating | |
| JP7224409B2 (en) | Lubricant coating for medical devices | |
| EP1957129B1 (en) | Hydrophilic coating comprising a polyelectrolyte | |
| EP2114477B1 (en) | Hydrophilic coating | |
| US6340465B1 (en) | Lubricious coatings for medical devices | |
| US8105666B2 (en) | Compliant polymeric coatings for insertable medical articles | |
| US20130197433A1 (en) | Lubricious medical device coating with low particulates | |
| WO2008027401A2 (en) | Low friction particulate coatings | |
| US10098989B2 (en) | Coatings for controlled release of water soluble drugs | |
| CN101365501B (en) | Hydrophilic coatings containing polyelectrolytes | |
| WO2014052283A1 (en) | Polyether-polyamide plastics for surgical applications | |
| DK2582745T3 (en) | COATING FORMULATION FOR PREPARING A HYDROPHIL COATING |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20131113 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20150818 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20160105 |